Amphastar Pharmaceuticals (AMPH) Tax Provisions (2013 - 2026)

Amphastar Pharmaceuticals' Tax Provisions history runs 14 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• On a quarterly basis, Tax Provisions fell 34.88% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $431000.0, a 98.62% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 91.99% from the prior year.
• Tax Provisions grew to $3.6 million in Q1 2026 per AMPH's latest filing, from -$15.7 million in the prior quarter.
• Across five years, Tax Provisions topped out at $14.0 million in Q3 2023 and bottomed at -$15.7 million in Q4 2025.
• The 5-year median for Tax Provisions is $6.0 million (2024), against an average of $5.4 million.
• Across the five-year window, Tax Provisions jumped 252.99% in 2022 and slumped 361.24% in 2025, its largest moves.
• Year by year, Tax Provisions stood at $7.3 million in 2022, then tumbled by 35.9% to $4.7 million in 2023, then grew by 28.35% to $6.0 million in 2024, then slumped by 361.24% to -$15.7 million in 2025, then soared by 123.18% to $3.6 million in 2026.
• Per Business Quant, the three latest AMPH Tax Provisions figures stand at $3.6 million (Q1 2026), -$15.7 million (Q4 2025), and $4.2 million (Q3 2025).